Page 36 - Sun Pharma
Sun Pharma shares down over 4% on Q3 net profit drops
The stock declined by 4.25% to end at Rs 622.50 on BSE. Intra-day, it lost 4.47% to Rs 621.05
 "Sun Pharma shares down over 4% on Q3 net profit drops")
Sun Pharma Q3 net dips 5% to Rs 1,471 cr on slower sales in US
Sun also said sales in its emerging markets rose 14% and those in the rest of the world were up 33%
 "Sun Pharma Q3 net dips 5% to Rs 1,471 cr on slower sales in US")
HC dismisses Sun Pharma's plea against Mylan on Oxaliplatin trademark case
Delhi High Court allows companies to approach bench after IPAB order
 "HC dismisses Sun Pharma's plea against Mylan on Oxaliplatin trademark case")
Sun Pharma to sell US arm Ohm Laboratories: Report
US market makes up half of Sun's revenue but business faces huge price erosion, regulatory issues
 "Sun Pharma to sell US arm Ohm Laboratories: Report")
Sun Pharma announces successful clinical trial for Seciera
Seciera is a patented, proprietary nanomicellar formulation of cyclosporine
 "Sun Pharma announces successful clinical trial for Seciera")
Sun Pharma: It is down but not out
Product acquisition gains partly offset losses because of pricing collusion probe in the US
 "Sun Pharma: It is down but not out")
Sun Pharma buys skin cancer drug Odomzo for $175 mn from Novartis
Sun Pharmaceutical was approved by the US drug regulator in July 2015
 "Sun Pharma buys skin cancer drug Odomzo for $175 mn from Novartis")
Sun Pharma steps up specialty biz, acquires cancer drug in $175 mn deal
The transaction gives Sun Pharma its first branded oncology product
 "Sun Pharma steps up specialty biz, acquires cancer drug in $175 mn deal")
Sun Pharma Advanced Research, Sun Pharma gain in weak market
SPARC was up 4% at Rs 320, while Sun Pharma up 1% at Rs 622 on the BSE, against 0.39% fall in Sensex at 09:27 am
 "Sun Pharma Advanced Research, Sun Pharma gain in weak market")
Sun Pharma extends fall; stock down 15% in 14 trading days
The stock dipped 2% to Rs 615 on the BSE, its lowest level since November 9, 2016
 "Sun Pharma extends fall; stock down 15% in 14 trading days")
Delay in Halol plant resolution to hurt Sun Pharma's FY18 profit
Credit Suisse cuts FY18 profit estimate by 5%
US FDA finds quality control problems at Sun Pharma's Halol plant
The violations listed by the FDA after its latest inspection at Halol include problems with Sun's quality control system
US FDA listed 9 observations in notice of concerns over Halol plant: Sun Pharma
US FDA inspected the facility from November 17-December 1, 2016
Sun Pharma gains after falling 6% on Wednesday
The company said none of the nine observations were characterized by the USFDA as repeat observations
US FDA raises fresh concerns on Sun Pharma's Halol plant
The Halol plant is a key manufacturing unit for Sun Pharma, which earns about half its revenue from the US market
Sun Pharma says US FDA finds more concerns at Halol plant
It is unclear what violations the FDA found; Sun did not disclose them
Sun Pharma dips 5% on confirmation of USFDA inspection of Halol facility
The stock was down 5% after the company confirms that Halol facility has undergone an inspection by USFDA
Sun Pharma tanks 4% on reports USFDA issued notice on Halol plant
The stock has shed 7% in the last 4 days, including today
 "Sun Pharma tanks 4% on reports USFDA issued notice on Halol plant")
Regulatory issues keep Sun Pharma stock under cloud
Stock is 40% below its all-time high touched last year
Sun Pharma's sharpens emerging market focus with $60 mn acquisition in Russia
Sun Pharma will pay $24 mn for 85% equity and will assume $36 mn debt as part of the transaction